Correlation between androgen receptor expression and FGF8 mRNA levels in patients with prostate cancer and benign prostatic hypertrophy

Q Wang, G W H Stamp, S Powell, P Abel, M Laniado, C Mahony, E-N Lalani, J Waxman

Abstract

Aim—To investigate the correlation between androgen receptor expression and fibroblast growth factor 8 (FGF8) mRNA levels.

Methods—39 human prostate cancers and 14 benign prostatic hypertrophy specimens were examined immunohistochemically for androgen receptor expression and by in situ hybridisation and reverse transcription polymerase chain reaction for FGF8 expression.

Results—In 39 tumours there was a statistically significant negative correlation between tumour grade and FGF8 expression and a positive correlation between FGF8 and androgen receptor expression. All 14 benign hypertrophy specimens expressed moderate to high levels of FGF8 and androgen receptor.

Conclusions—Loss of FGF8 may be a factor involved in the development of prostatic cancer.

Keywords: fibroblast growth factor 8; in situ hybridisation; androgen receptor; immunohistochemistry

Prostate cancer is the second most common cause of male death cancers in the Western world. Currently 13 300 men each year develop prostate cancer and 8800 die in England and Wales. The majority of patients with prostate cancer respond to androgen withdrawal treatment by medical orchietomy or with antiandrogens. This effect is transient, and eventually the majority of prostate tumours become androgen independent. It is possible that growth factors or cytokines may contribute to the development of androgen independence, and the stromal fibroblast proliferation that is a feature of this cancer. Fibroblast growth factors (FGF) are multifunctional, heparin binding polypeptides which share structural similarity. Ten members of this family have currently been identified. Signalling is mediated by a group of transmembrane tyrosine kinase receptors, known as the fibroblast growth factor receptors (FGFR) 1–4, which show structural and functional diversity. Fibroblast growth factors and their receptors are involved in the process of development, wound healing, angiogenesis, and tumorigenesis. FGF8 is also known as androgen induced growth factor (AIGF), and is of potential interest in prostatic neoplasms. In an initial observation Leung et al have shown a positive relation between FGF8 mRNA expression and tumour grade in patients with prostatic cancer. FGF8 was initially isolated from the conditioned medium of androgen dependent mouse mammary cancer cell line SC-3 after testosterone stimulation. The human FGF8 gene is located on chromosome 10q25-26 and the nucleotide sequences are highly conserved. Alternate splicing of the first exon of the FGF8 gene generates four different transcripts and results in four protein isoforms that differ at the amino terminus. However, the biological significance of the multiple FGF8 protein isoforms is unknown.

The murine homologue has 100% homology at the protein level with human FGF8, and the gene is detectable in the testes and ovaries of the adult mouse. In humans, FGF8 expression is confined to testis, prostate, and kidney. FGF8 is transcriptionally activated by the mouse mammary tumour virus, suggesting that the gene may be a proto-oncogene. This view is supported by the observation that FGF8 can transform NIH3T3 cells and that FGF8 and the mouse mammary tumour virus MMTV lead to tumour formation in Wnt-1 mice.

Overexpression of fibroblast growth factors or members of the FGFR family has been observed in many different carcinomas and may have an important role in hormone dependent malignancies. FGFB/bFGF functions as a growth factor in the benign and malignant prostate. FGF-7, which is also known as keratinocyte growth factor (KGF), is involved in paracrine interactions between mesenchyme and epithelium in normal and malignant prostate.

In prostate cancer, FGF8 expression is detectable in the androgen responsive cell line LNCaP and the unresponsive cell lines PC-3, DU145, and ALVA-31. Recombinant FGF8 stimulates the growth of LNCaP but not PC-3. Three human FGF8 gene isoforms—FGF8a, FGF8b, and FGF8e—have been isolated from the DU145 cell line and transformation of NIH3T3 cells by these three isoforms leads to tumour formation in nude mice. The primary aim of this study was to determine whether there was a statistically significant relation between FGF8 mRNA and androgen receptor protein expression in patients with prostate cancer or benign hypertrophy, as might be expected from the in vitro data. We have investigated FGF8 gene expression in benign and malignant prostate by in situ hybridisation and reverse transcription
polymerase chain reaction (RT-PCR), and compared gene expression with androgen receptor expression determined by immunohistochemistry, because of the potential relevance of FGF8 to prostate cancer progression. FGF8 mRNA was expressed in all 14 benign prostatic hypertrophy specimens that we examined. In 39 tumours there was a negative correlation between tumour grade and FGF8 expression and a positive correlation between FGF8 and androgen receptor expression.

Methods

SAMPLES
All chemicals were purchased from Sigma unless otherwise stated.

Benign and malignant prostate samples from untreated patients, obtained by transurethral resection between 1990 and 1996, were routinely processed, formalin fixed, paraffin embedded, and subsequently retrieved from the Hammersmith and Ealing hospitals surgical archives. Serial sections (5 µm thickness) from 53 samples from 14 patients with benign prostatic hyperplasia and from 39 patients with prostate cancer were cut and processed for in situ hybridisation, immunohistochemistry, and histological assessment using the Gleason grading system. Full term placental tissue was used as the positive control.

IN SITU HYBRIDISATION

FGF8 cDNA was isolated by RT-PCR from an ovarian carcinoma cell line. The PCR product of this reaction was shot gun cloned into the pCR3 vector (Invitrogen). The insert fragment was 714 bp from position 1 to 714 of the FGF8 cDNA sequence, corresponding to the FGFα isoform. Antisense and sense riboprobes were generated using SP6 and T7 RNA polymerases, respectively. A 1 kb β actin antisense riboprobe was used as a positive control for the detection of hybridisable mRNA in tissues, as described previously.

Riboprobes labelled with $^{35}$S were synthesised from cDNA cloned in vectors, using RNA polymerases; 0.5–1.0 µg of linearised template were incubated with 2.5 µl of 5× transcription buffer, 2 units of RNAsin (Promega), 5.6 mM of dithiothreitol (DTT), 1.0 mM each of ATP, guanosine triphosphate (GTP), and cytosine triphosphate (CTP), 14.0 µM of $^{35}$S-uridine triphosphate (Amersham International), and 5 units of RNA polymerase (Promega), made up to a total volume of 12.5 µl for one hour at 37°C. The template was then destroyed by adding 1 µl of DNase (Promega) at 37°C for 15 minutes. The reactions were diluted with 25 µl of 10 mM DTT and 1.5 µl of ribosomal RNA (10 mg/ml) (Boehringer Man-

---

**Figure 1** (A) Very strong hybridisation of β actin mRNA in both epithelial and stromal cells serving as a positive control. (B) Placental tissue a positive control for FGF8 mRNA showing labelling of the trophoblastic cells.

**Figure 2** A benign gland in nodular hyperplasia showing uniform, relatively even grain distribution of labelled FGF8 (+++) over the epithelial cells, with sparse hybridisation to stromal fibroblasts. A corresponding section hybridised with the sense probe was negative.
Unincorporated nucleotides were removed by centrifugation in a Chromaspin-30 column (Clontech) and the integrity of the probes was confirmed by gel electrophoresis. Sections were deparaffinised in xylene under RNAse limited conditions, soaked in phosphate buffered saline (PBS), pH 7.2–7.4, and then subjected to proteinase K treatment (20 mg/ml) in PBS for 10 minutes at 37°C. Sections were fixed in 4% paraformaldehyde for 20 minutes and then treated with 0.25% acetic anhydride in 0.1 M triethanolamine for 10 minutes, hybridised with α35S labelled ribo-probe (1×10⁶ cpm/section), and incubated at 55°C overnight. After hybridisation, the sections were washed for 60 minutes in 50% formamide buffer (50% formamide, 300 mM NaCl, 10 mM Na2HPO4, 10 mM Tris/HCl, 50 mM EDTA) at 55°C three times and then washed in TNE buffer (0.1 M NaCl, 10 mM Tris, 1 mM EDTA) at 37°C for five minutes. The sections were then treated with RNase A (100 mg/ml) at 37°C for one hour, washed twice in 2× SSC (NaCl/sodium citrate) at 65°C for one hour, and then in 0.5× SSC for a further 30 minutes.

Autoradiography was carried out by dipping the sections in K5 emulsion (Ilford), exposing them for 10 to 20 days at 4°C and developed in D19 (Kodak). They were counterstained with haematoxylin. All sections were initially assessed by the same observer who was blind of androgen receptor status.

**RT-PCR**

Ten benign prostatic hyperplasia specimens and four tumours were examined to confirm the expression of FGF8 mRNA using RT-PCR. Frozen samples were homogenised and total RNA was extracted using the RNAzol™ method (Biogenesis). RNA pellets were washed with 70% ethanol and dissolved in water.

cDNA was synthesised using Moloney murine leukaemia virus (MMLV) reverse transcriptase (Gibco). Two micrograms of RNA were incubated with 0.5 µg of oligo (dT) 12–18 primer in a total volume of 10 µl at 70°C for 15 minutes. The samples were then placed on ice and 200 units of mouse MMLV reverse transcriptase were added, together with a 1/5 volume of 5× reverse transcriptase buffer, 40 units of RNAse inhibitor, and 0.5 mM of dATP, dCTP, dGTP, and dTTP (Promega) to give a final volume of 20 µl. The mixture was then reverse transcribed at 42°C for one hour, after which one tenth of each transcription reaction was amplified in 50 µl solutions including 1× Taq DNA polymerase buffer (Promega), 2.5 mM of MgCl2, 0.5 mM of dNTPs, 2.5 units of Taq DNA polymerase, and 100 ng each of primers RB376 (5’AAAG-GCAAGGACTGCGTCTTCACG3’) and RB359 (5’CGTGAAGGGCGGGTAGTTGAG3’), under PCR conditions: 95°C for five minutes, then 30 cycles of 94°C for one minute, 65°C for one minute, and 72°C for three minutes.

**IMMUNOHISTOCHEMISTRY**

Sections were dewaxed, rehydrated, and then treated in a microwave oven at 700 watts in 0.01 M trisodium citrate, pH 6.0, for five minutes. The sections were then blocked with 3% bovine serum albumin (BSA) in PBS for 60 minutes, treated with mouse antiandrogen...
receptor antibody (1:100; Biogenex), and incubated overnight. Sections were biotinylated with rabbit antimouse immunoglobulin (Dako) for 60 minutes and peroxidase conjugated with streptavidin (1:200) for a further 60 minutes. This was followed by an additional two washes for five minutes in PBS. Enzyme activity was developed with 1 mg/ml 3.3'-diaminobenzidine tetrahydrochloride (DAB) and counterstained with haematoxylin.

STATISTICS

The χ² test was used to calculate the correlation between FGF8 mRNA expression and Gleason grade, androgen receptor expression and Gleason grade, and FGF8 mRNA expression and androgen receptor immunohistochemistry.

RESULTS

FGF8 RNA EXPRESSION BY IN SITU HYBRIDISATION

In situ hybridisation was evaluated according to the percentage of cells labelled and the degree of labelling, where ± indicated equivocal labelling of 50–100 grains/cell, + indicated weak labelling equivalent to 100–200 grains/cell, ++ moderate labelling of 200–500 grains/cell, and +++ strong labelling of more than 500 grains/cell. All samples expressed +++ for β-actin, showing that RNA was well preserved (fig 1A).

Placental trophoblasts were used as a positive control for FGF8 labelling (fig 1B). FGF8 labelling in epithelial cells in benign prostatic hyperplasia was uniformly distributed (fig 2). Stromal expression of FGF8 labelling was observed in some desmoplastic stromal fibroblasts, and was most prominent in hyperplastic stromal nodules. Six of the 14 benign prostatic hyperplasia specimens showed ++ labelling and eight of 14 showed +++ labelling.

FGF8 labelling was examined in 39 prostatic cancers (figs 3 and 4). There were no Gleason grade (GG) 1 tumours. One of five GG2 tumours did not express FGF8, one showed + labelling and three +++ labelling. One of 16 GG3 tumours showed no labelling, one + labelling, seven ++ labelling, and seven +++ labelling. Two of 13 GG4 tumours showed no labelling, four + labelling, six ++ labelling, and one +++ labelling. One of five GG5 tumours showed no labelling of FGF8, three + labelling, and one ++ labelling. Statistical analysis showed a negative correlation between Gleason grade and FGF8 gene labelling in prostatic tumours (p = 0.02; table 1) which was maximal in the moderately differentiated tumours and significantly lower in the high grade tumours.

ANDROGEN RECEPTOR EXPRESSION

All samples expressed androgen receptor to variable degrees (figs 5 and 6). Two of 14 benign prostatic hyperplasia specimens had + staining intensity, 11 ++, and one ++++. One of five GG2 tumours did not express FGF8, one showed + labelling, and three +++ labelling. One of 16 GG3 tumours showed no labelling, one + labelling, seven ++ labelling, and seven ++++ labelling. Two of 13 GG4 tumours showed no labelling, four + labelling, six ++ labelling, and one ++++ labelling. One of five GG5 tumours showed no labelling of FGF8, three + labelling, and one ++ labelling. Statistical analysis showed a negative correlation between Gleason grade and androgen receptor expression (p = 0.003; table 2).

Table 2 Correlation between Gleason grade and androgen receptor expression in benign and malignant prostate tissue

<table>
<thead>
<tr>
<th>Androgen receptor expression</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>+</td>
<td>14</td>
</tr>
<tr>
<td>++</td>
<td>16</td>
</tr>
<tr>
<td>+++</td>
<td>3</td>
</tr>
<tr>
<td>BPH</td>
<td></td>
</tr>
<tr>
<td>G2</td>
<td>1</td>
</tr>
<tr>
<td>G3</td>
<td>1</td>
</tr>
<tr>
<td>G4</td>
<td>7</td>
</tr>
<tr>
<td>G5</td>
<td>5</td>
</tr>
<tr>
<td>p = 0.003</td>
<td></td>
</tr>
</tbody>
</table>

BPH, benign prostatic hypertrophy.

Figure 4 Weak (+) labelling of a Gleason grade 4 prostatic carcinoma for FGF8 35S-labelled riboprobe with autoradiography.

Figure 6 Immunostaining showed weak and heterogeneous reactivity for androgen receptor in the same tumour shown in fig 5.

CORRELATION BETWEEN FGF8 mRNA EXPRESSION AND ANDROGEN RECEPTOR EXPRESSION IN PROSTATE TUMOURS

FGF8 mRNA labelling and androgen receptor immunostaining intensity was compared in the 39 tumours. The five FGF8 mRNA negative samples all showed androgen receptor + staining intensity. Five of nine + FGF8 staining samples had + androgen receptor staining and four showed ++ androgen receptor staining.
Four of 14 ++ FGF8 expressing tumours showed + androgen receptor labelling, and 10 ++ labelling. Five of 11 FGF8 +++ tumours exhibited ++ androgen receptor labelling, and six +++ labelling. There was a strong positive correlation between androgen receptor staining intensity and FGF8 expression (p < 0.001; table 3).

Discussion

We have investigated FGF8 mRNA expression by in situ hybridisation and androgen receptor expression by immunohistochemistry in malignant and benign prostatic hyperplasia specimens. FGF8 mRNA was detected in 14 benign prostatic hyperplasia specimens in a relatively uniform fashion. There were moderate or high levels of hybridisation on epithelial as compared with stromal cells, apart from hyperplastic stromal nodules. In malignant prostatic hyperplasia the greatest hybridisation was seen in moderate or well differentiated carcinomas and considerably less in poorly differentiated carcinomas.

All samples expressed androgen receptor to a variable degree in epithelial cells. The majority of benign prostatic hyperplasia specimens showed uniform, moderate degrees of androgen receptor expression. Most (67%) poorly differentiated carcinomas (GG4 and GG5) showed low androgen receptor immunoreactivity which was often heterogeneous, while the majority (~90%) of low grade carcinomas showed moderate to high immunoreactivity.

There was a significant positive correlation between the levels of androgen receptor expression and FGF8 mRNA in malignant prostatic epithelial cells. Stromal expression of androgen receptor corresponded to weak but definite FGF8 hybridisation in benign stromal nodules.

Our results are not in agreement with previously published in situ hybridisation data. Using a digoxigenin labelling antisense riboprobe in 31 prostate cancers, Leung et al reported that the highest levels of FGF8 expression were seen in poorly differentiated tumour cells: in five benign prostatic hyperplasia cases there was no FGF8 expression in either epithelial or stromal cells, while some “benign” basal cells in the epithelium adjacent to tumour expressed FGF8 at low to moderate intensity.

In view of this discrepancy between our results and those of Leung et al, we proceeded to a further assessment of FGF8 mRNA expression by RT-PCR. All 10 benign hyperplasia specimens and the four tumours showed FGF8 gene expression and this result is consistent with the findings of Ghosh et al. Our study, the majority of FGF8 expression was by epithelial cells, as evidenced by in situ hybridisation observations. The expression of FGF8 mRNA in tumours was within both malignant and benign elements.

Although there are conflicting views about the levels of androgen receptor expression in well differentiated adenocarcinomatous epithelium as compared with moderately and poorly differentiated carcinomas, our results have shown an inverse correlation between grade and androgen receptor expression in prostate cancer, suggesting that FGF8 loss may be a factor or a marker of genetic change in tumour development. It should be noted that the finding of immunoreactive androgen receptor does not provide conclusive evidence for the presence of a structurally intact, functionally active hormone binding receptor, and mutations in the androgen receptor gene can occur in androgen independent prostate cancer.

Our observation of a positive correlation between FGF8 mRNA and androgen receptor expression in prostate cancer suggests that there may be androgen regulation of FGF8 expression and supports previous observations that FGF8 is an androgen dependent growth factor. Sato et al showed that an androgen induced autocrine loop regulated cell growth in the SC-3 mouse mammary cancer cell line. In their proposed model, stimulation of the SC-3 cells by androgen leads to binding of the activated androgen receptor–androgen complex to the androgen response element of the FGF8 gene, inducing transcription and translation, further binding with a mutated FGFR1 and transformation. However, in contrast to SC-3 cells, the significance of FGF8 in the growth of human prostate cancer is not clearly understood. It is possible that FGF8 could be implicated in a paracrine loop in prostate cancer, confirming the views of Ohuchi et al.

In summary, our study has shown that FGF8 mRNA is expressed in benign prostatic hyper-

Table 3  Correlation between FGF8 gene and androgen receptor expression in malignant prostate tissue

<table>
<thead>
<tr>
<th>Androgen receptor</th>
<th>−</th>
<th>+</th>
<th>++</th>
<th>+++</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>+</td>
<td>5</td>
<td>5</td>
<td>4</td>
<td>0</td>
<td>14</td>
</tr>
<tr>
<td>++</td>
<td>0</td>
<td>4</td>
<td>10</td>
<td>5</td>
<td>19</td>
</tr>
<tr>
<td>+++</td>
<td>0</td>
<td>0</td>
<td>6</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Total</td>
<td>5</td>
<td>9</td>
<td>14</td>
<td>11</td>
<td>39</td>
</tr>
</tbody>
</table>

p < 0.001

Figure 7  FGF8 gene expression by reverse transcription polymerase chain reaction (PCR). Lanes 1–4: BPH; lanes 5–6: prostate cancers; lane 7: molecular weight. All specimens have a 244 bp PCR product.
plasia and that there is a positive correlation between expression of FGFR2 mRNA and androgen receptor protein in prostate adenocarcinomas, and an inverse correlation with tumour grade. We suggest that there should be an evaluation of androgen receptor and FGFR2 expression in relation to clinical prognostic factors in prostate cancer.

Correlation between androgen receptor expression and FGF8 mRNA levels in patients with prostate cancer and benign prostatic hypertrophy.

Q Wang, G W Stamp, S Powell, P Abel, M Laniado, C Mahony, E N Lalani and J Waxman

*J Clin Pathol* 1999 52: 29-34
doi: 10.1136/jcp.52.1.29

Updated information and services can be found at:
http://jcp.bmj.com/content/52/1/29

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/